These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 37946113

  • 1. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
    Zhou Z, Urman R, Gill K, Park AS, Vuvu F, Patel LB, Lu J, Wade RL, Frerichs L, Bensink ME.
    J Headache Pain; 2023 Nov 09; 24(1):153. PubMed ID: 37946113
    [Abstract] [Full Text] [Related]

  • 2. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication.
    Varnado OJ, Hoyt M, Ye W, Nicholson R.
    Curr Med Res Opin; 2022 Aug 09; 38(8):1451-1457. PubMed ID: 35762152
    [Abstract] [Full Text] [Related]

  • 3. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB.
    Headache; 2020 Sep 09; 60(8):1734-1742. PubMed ID: 32799325
    [Abstract] [Full Text] [Related]

  • 4. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
    Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R.
    J Manag Care Spec Pharm; 2022 Aug 09; 28(8):818-829. PubMed ID: 35876297
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment Patterns, Healthcare Resource Utilization, and Direct Costs Among Patients Initiating Concomitant Use of a Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRP mAb) and Novel Acute Medication in the United States.
    Varnado OJ, Gulati T, Wheeler A, Hoyt M.
    Patient Prefer Adherence; 2023 Aug 09; 17():3449-3459. PubMed ID: 38143945
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Changes in use of acute and preventive medications for migraine after erenumab initiation over 12 months: A United States retrospective cohort study.
    Multani JK, Urman R, Park AS, Gill K, Vuvu F, Sun K, Patel LB, Stockl KM, Hawkins K, Rhyne C, Bensink ME.
    Headache; 2024 Sep 09. PubMed ID: 39248147
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study.
    Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R.
    Patient Prefer Adherence; 2022 Sep 09; 16():821-839. PubMed ID: 35378732
    [Abstract] [Full Text] [Related]

  • 13. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC, Schwedt TJ.
    Prog Brain Res; 2020 Sep 09; 255():143-170. PubMed ID: 33008505
    [Abstract] [Full Text] [Related]

  • 14. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
    Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P.
    Handb Clin Neurol; 2024 Sep 09; 199():107-124. PubMed ID: 38307640
    [Abstract] [Full Text] [Related]

  • 15. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ.
    Headache; 2018 Nov 09; 58 Suppl 3():238-275. PubMed ID: 30242830
    [Abstract] [Full Text] [Related]

  • 16. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M, Vuong T, Taura T, Wilson DS, Stratton JR, Mackenzie KD.
    Cephalalgia; 2021 Apr 09; 41(5):499-514. PubMed ID: 33626922
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Porreca F, Navratilova E, Hirman J, van den Brink AM, Lipton RB, Dodick DW.
    Cephalalgia; 2024 Mar 09; 44(3):3331024241238153. PubMed ID: 38477313
    [Abstract] [Full Text] [Related]

  • 20. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
    Nagaraj K, Vandenbussche N, Goadsby PJ.
    Neurol India; 2021 Mar 09; 69(Supplement):S59-S66. PubMed ID: 34003149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.